
De-extinction startup Colossal Biosciences seeks new funding at $20-$30 billion valuation
De-extinction startup Colossal Biosciences is reportedly in talks to raise new funding at a $20-$30 billion valuation, a significant increase from its previous $10.2 billion. The company has begun generating revenue from conservation technology, spun-off startups, and plans for artificial womb technology and biodiversity credits.





